192 related articles for article (PubMed ID: 36465977)
1. Development of an Effective Therapy for Alkaptonuria - Lessons for Osteoarthritis.
Gallagher JA; Dillon JP; Ranganath LR
Rheumatol Immunol Res; 2021 Jun; 2(2):79-85. PubMed ID: 36465977
[TBL] [Abstract][Full Text] [Related]
2. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
[TBL] [Abstract][Full Text] [Related]
3. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
[TBL] [Abstract][Full Text] [Related]
4. Alkaptonuria: Current Perspectives.
Zatkova A; Ranganath L; Kadasi L
Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
[TBL] [Abstract][Full Text] [Related]
5. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
[TBL] [Abstract][Full Text] [Related]
7. Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing.
Taylor AM; Hsueh MF; Ranganath LR; Gallagher JA; Dillon JP; Huebner JL; Catterall JB; Kraus VB
Rheumatology (Oxford); 2017 Jan; 56(1):156-164. PubMed ID: 28028161
[TBL] [Abstract][Full Text] [Related]
8. Alkaptonuria: An example of a "fundamental disease"--A rare disease with important lessons for more common disorders.
Gallagher JA; Dillon JP; Sireau N; Timmis O; Ranganath LR
Semin Cell Dev Biol; 2016 Apr; 52():53-7. PubMed ID: 26891864
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress and mechanisms of ochronosis in alkaptonuria.
Braconi D; Millucci L; Bernardini G; Santucci A
Free Radic Biol Med; 2015 Nov; 88(Pt A):70-80. PubMed ID: 25733348
[TBL] [Abstract][Full Text] [Related]
10. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
[TBL] [Abstract][Full Text] [Related]
11. Alkaptonuria: a very rare metabolic disorder.
Aquaron R
Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
[TBL] [Abstract][Full Text] [Related]
12. Homogentisic acid induces autophagy alterations leading to chondroptosis in human chondrocytes: Implications in Alkaptonuria.
Galderisi S; Milella MS; Rossi M; Cicaloni V; Rossi R; Giustarini D; Spiga O; Tinti L; Salvini L; Tinti C; Braconi D; Millucci L; Lupetti P; Prischi F; Bernardini G; Santucci A
Arch Biochem Biophys; 2022 Mar; 717():109137. PubMed ID: 35090868
[TBL] [Abstract][Full Text] [Related]
13. Nutritional interventions for patients with alkaptonuria: A minireview.
Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
[TBL] [Abstract][Full Text] [Related]
14. Development of an in vitro model to investigate joint ochronosis in alkaptonuria.
Tinti L; Taylor AM; Santucci A; Wlodarski B; Wilson PJ; Jarvis JC; Fraser WD; Davidson JS; Ranganath LR; Gallagher JA
Rheumatology (Oxford); 2011 Feb; 50(2):271-7. PubMed ID: 20952450
[TBL] [Abstract][Full Text] [Related]
15. Alkaptonuria.
Mistry JB; Bukhari M; Taylor AM
Rare Dis; 2013; 1():e27475. PubMed ID: 25003018
[TBL] [Abstract][Full Text] [Related]
16. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
[TBL] [Abstract][Full Text] [Related]
17. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
18. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Phenotype Differences in Siblings with Alkaptonuria.
Zatkova A; Olsson B; Ranganath LR; Imrich R
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295892
[TBL] [Abstract][Full Text] [Related]
20. Alkaptonuria in Russia.
Soltysova A; Kuzin A; Samarkina E; Zatkova A
Eur J Hum Genet; 2022 Feb; 30(2):237-242. PubMed ID: 34504318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
